Skip to main content
PharmaBlock Sciences (Nanjing), Inc. logo

PharmaBlock Sciences (Nanjing), Inc. — Investor Relations & Filings

Ticker · 300725 ISIN · CNE1000035K5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,618 across all filing types
Latest filing 2024-04-23 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300725

About PharmaBlock Sciences (Nanjing), Inc.

https://www.pharmablock.com

PharmaBlock Sciences (Nanjing), Inc. specializes in the design and manufacture of innovative building blocks and provides integrated chemistry services for drug discovery and development. The company offers a comprehensive portfolio of structurally diverse scaffolds and intermediates used to enhance the efficiency of medicinal chemistry. Its core capabilities include process research and development, scale-up production, and commercial-scale manufacturing under CDMO frameworks. By utilizing advanced chemical technologies and a vast library of unique chemical entities, the company supports global biotechnology and pharmaceutical organizations in streamlining their research pipelines and optimizing the transition from discovery to clinical development and commercialization.

Recent filings

Filing Released Lang Actions
华泰联合证券有限责任公司关于南京药石科技股份有限公司2024年度对外担保额度预计的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from Huatai United Securities Co., Ltd. regarding the expected external guarantee limit for the year 2024 for Nanjing Yaoshi Technology Co., Ltd. It includes financial data, guarantee scope, approval procedures, and opinions from the board and supervisory committee. The document is not a full financial report but rather a regulatory or compliance-related verification statement concerning guarantee limits and related approvals. It does not contain comprehensive financial statements or quarterly/yearly financial results. The document length is 3318 characters, which is relatively short and more consistent with a regulatory or compliance filing rather than a full report. It is not an announcement of a report publication but a formal verification opinion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory or compliance documents that do not fit other specific categories.
2024-04-23 Chinese
华泰联合证券有限责任公司关于南京药石科技股份有限公司签订《股份回购及相关事宜的条款清单》暨关联交易的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Huatai United Securities Co., Ltd. regarding the signing of a term sheet for a share repurchase and related matters involving Nanjing Yaoshi Technology Co., Ltd. It includes information about the related party transaction, the terms of the share repurchase, financial data of the related company, and the independent directors' and sponsor's opinions. The document is focused on a specific capital transaction involving share repurchase and related agreements, with detailed terms and pricing. It is not a full financial report, audit report, or earnings release. It is not a regulatory filing or announcement of a report publication. The content fits best under Capital/Financing Update (CAP) as it provides updates on company financing activities and capital structure changes related to the share repurchase transaction.
2024-04-23 Chinese
2023年年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled '南京药石科技股份有限公司 审计报告' which translates to 'Nanjing Yaoshi Technology Co., Ltd. Audit Report'. It contains detailed audit opinions, audit basis, key audit matters, and extensive financial statements including consolidated balance sheets, income statements, cash flow statements, and changes in equity. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement. The content is consistent with a standalone audit report, including auditor's opinion and detailed financial data, rather than a full annual report or other filing types. Therefore, the document fits the definition of an Audit Report / Information (AR).
2024-04-23 Chinese
华泰联合证券有限责任公司关于南京药石科技股份有限公司2024年度开展外汇衍生品交易业务的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from Huatai United Securities Co., Ltd. regarding Nanjing Yaoshi Technology Co., Ltd.'s plan to conduct foreign exchange derivative trading business in 2024. It includes investment purpose, amount, methods, risk analysis, risk control measures, accounting principles, and the sponsor's verification opinion. The document references board and supervisory meetings approving the plan and mentions the need for shareholder approval. It is not a financial report like an annual or interim report, nor is it a simple announcement or certification. It is a regulatory compliance and verification report related to a specific financial activity (foreign exchange derivatives trading) and the sponsor's opinion on it. This fits best under Regulatory Filings (RNS) as it is a compliance-related document that does not fit other specific categories such as capital update or audit report. The document length is under 5,000 characters, but it contains substantive content, not just an announcement of a report publication, so it is not RPA. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2024-04-23 Chinese
投资者关系管理制度
Governance Information Classification · 95% confidence The document is titled as an "Investor Relations Management System" for a company, detailing policies, principles, and procedures for managing communication and information disclosure with investors. It extensively covers governance, communication channels, compliance with securities laws, and investor engagement practices. There is no financial data, earnings information, voting results, or announcements of specific events. It is a governance-related document focusing on investor relations management policies and internal rules. Therefore, it fits best under Governance Information (CGR). The document length is substantial and contains detailed governance content rather than a brief announcement or regulatory filing.
2024-04-23 Chinese
关于公司续聘2024年度审计机构的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the company's decision to reappoint its audit firm for the 2024 fiscal year. It details the selection process, qualifications of the audit firm, audit fees, and approvals by the board and supervisory committee. It does not contain any actual audit report, financial statements, or audit results. The document is relatively short (3129 characters) and serves as a formal announcement of the audit firm appointment, pending shareholder approval. Therefore, it is not an Audit Report (AR) itself but an announcement related to audit firm appointment. Given the nature and content, the best fitting category is Regulatory Filings (RNS), as it is a regulatory announcement about audit firm reappointment without the audit report attached.
2024-04-23 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.